Podoplanin (PDPN) is a transmembrane receptor glycoprotein that is upregulated on transformed cells, cancer associated fibroblasts and inflammatory macrophages that contribute to cancer progression. In particular, PDPN increases tumor cell clonal capacity, epithelial mesenchymal transition, migration, invasion, metastasis and inflammation. Antibodies, CAR-T cells, biologics and synthetic compounds that target PDPN can inhibit cancer progression and septic inflammation in preclinical models. This review describes recent advances in how PDPN may be used as a biomarker and therapeutic target for many types of cancer, including glioma, squamous cell carcinoma, mesothelioma and melanoma.
Podoplanin expression is induced by tumor promoters including TPA, RAS and Src. [5] [6] [7] For example, the Src tyrosine kinase utilizes the focal adhesion adaptor protein Cas/BCAR1 to induce PDPN expression to promote tumor cell motility. 5 Src is a nonreceptor protein kinase that promotes nonanchored tumor cell growth and migration required for invasion and metastasis. Src is not mutated in most cancers. However, Src activity is associated with many types of human cancer, including tumors of the colon, breast, pancreas, brain and skin. 8, 9 Cells transformed by a variety of chemicals, viral agents and oncogenes, including the Src tyrosine kinase, can be normalized by contact with nontransformed cells. This process, called "contact normalization" can force transformed cells to assume a normal morphology and reside in many organs, including breast, intestine and skin, for many years. [10] [11] [12] 
CLEC-2 protein itself induces E-cadherin expression, downregulates
RhoA GTPase and suppresses NHEK cell migration. Taken together, these data suggest that PDPN interacts with CLEC-2 to modulate E- Figure 1 ). [28] [29] [30] [31] [32] [33] [34] Thus, PDPN-CLEC-2 interaction offers a unique opportunity to develop anticancer strategies. [35] [36] [37] Antibodies can be utilized to disrupt PDPN-CLEC-2 interaction. 36, 38 For example, the NZ-1 antibody, its derivatives (eg NZ-8, shown in Figure 1 . 33, 43 As the first defined CLEC-2 antagonist, 2CP not only possesses anti-cancer metastatic activity but also enlarges the therapeutic efficacy of cisplatin while decreasing the risk of bleeding in experimental metastasis models.
Interactions between PDPN and CLEC-2 can also be blocked to modulate the inflammatory response in sepsis, which is often associated with cancer progression and treatments. Indeed, sepsis is a lifethreatening, severe systemic inflammatory response associated with multiple organ failure and death, which affects over 19 million patients annually. 44, 45 Thrombocytopenia is common in sepsis and severe thrombocytopenia is associated with poor outcome in septic patients and mice. [46] [47] [48] Platelets are now recognized as critical immunomodulators affecting immune cell recruitment, releasing cytokines and chemokines and trapping bacteria. 49 Platelet depletion or inhibition of platelet activation results in a decrease in survival from sepsis. 49, 50 Moreover, platelets maintain vascular integrity at the site of inflammation through the PDPN and collagen/fibrin receptors, CLEC-2 and glycoprotein VI (GPVI), respectively. [51] [52] [53] In sepsis, platelet interaction with inflammatory macrophages dampens macrophages pro-inflammatory phenotype and decrease the secretion of TNF-a. 50 Recent studies indicate that platelet CLEC-2 inter- In addition to basic amino acids, the intracellular domain of PDPN also contains 2 conserved serine residues, which were long considered to be putative phosphorylation sites. 15, 56, 57 The functional relevance of these serine residues was elucidated by mutagenesis and cell motility experiments. Interestingly, phosphorylation of serines inhibits PDPN-mediated cell migration. Furthermore, both serines need to be phosphorylated to inhibit cell migration. 4, 58 Phosphorylation can modify the structural conformation of amino acids in the PDPN intracellular domain, as shown in Figure 3 .
The kinases that can phosphorylate PDPN cytoplasmic serine residues were identified as protein kinase A (PKA) and cyclin-dependent kinase 5 (CDK5), as shown in Figure 1 . While PKA can phosphorylate either of the 2 serines (S167 or S171 in mouse PDPN), CDK5 preferably phosphorylates the C-terminal serine (S171 in mouse PDPN). 4 These data suggest a scenario in which PKA and of major histocompatibility complex (MHC) restriction, which is often downregulated in gliomas. 63 Third generation CAR, that include 2 costimulatory domains such as CD28 and 4-1BB (CD137), have been described and are highly likely to lyse tumor cells. 64 Several CAR have been generated against antigens expressed in GBM, including epidermal growth factor receptor variant III (EGFRvIII), human epidermal growth factor receptor 2 (HER2), interleukin-13 receptor alpha 2 (IL13Ra2), and, as described here, PDPN. 24 In particular, a lentiviral vector has been constructed with One concern with PDPN CAR-T therapy arises from nonspecific lysis of normal cells that express PDPN, including lymphatic endothelium and type I lung alveolar cells. Cancer-specific monoclonal antibodies (CasMabs) have been generated to address this concern. These PDPN CasMabs react with PDPN expressed by cancer cells, but not normal cells. 65 These should be extremely useful reagents to produce very specific CAR-T therapies that target PDPN to combat glioma and other cancers.
As with most other anticancer therapies, it is important to has been used to demonstrate efficacy of the anti-PDPN compounds, including MASL on oral squamous cell carcinoma and melanoma xenografts. 17, 27 This approach can be used to gather critical information that can be reported back to oncologists in charge of treatment planning in less than 5 days after surgery.
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